Clinical Trials Logo

Clinical Trial Summary

Purpose: To evaluate reactions to and opinions of a messaging campaign.

Participants: Participants will be recruited through Prime Panels and will be US-based adults (18 years old and older) who consumed red meat in the past 30 days.

Procedures (methods): After completing a screening question about meat consumption, participants will review a consent form. If they select to participate in the study, participants will be randomly assigned to view control messages, red meat-related environment messages, or red meat-related health messages. They will be asked a series of questions about these messages.

Participants will also be asked about grocery shopping preferences and standard demographics questions.


Clinical Trial Description

Excess consumption of red and processed meat is a growing problem, especially in the United States where meat is consumed more than three times the global average. Epidemiological evidence for the association between excess meat intake and negative health outcomes (such as cancer, cardiovascular disease, and type 2 diabetes) as well as negative environmental impacts (such as pollution, overuse of resources, and carbon emissions) indicates that reducing meat consumption should be particularly pertinent to researchers and other public health professionals.

The potential of using widespread communication campaigns, such as Meatless Monday, to reduce meat consumption by educating individuals on the associated health and environmental risks appears to be promising. However, the current literature is missing information regarding what types of messages are most effective (e.g. negative environmental messages vs. negative health messages). To address this knowledge gap, our study will collect quantitative data in measurable outcomes to understand effectiveness and comprehension of environmental messages and health messages to reduce meat consumption.

Setting: This is an online study using Qualtrics, so this research does not involve talking to human participants.

Recruitment: Participants will be recruited through Prime Panels, a survey research firm through which participants voluntarily sign up to participate in research studies.

Informed Consent: Participants will read a written consent document that includes information about the study's purpose, expectations, and possible risks and benefits. Participants will acknowledge that they have read and agreed to the terms by clicking forward.

Randomization: Participants will be randomly assigned to one of three groups: 1) control (about checking their credit score), 2) environment-focused Meatless Monday messages, or 3) health-focused Meatless Monday messages.

Assessment: Using an online platform (Qualtrics), participants will answer a screening question about red meat consumption. If they are eligible (consumption of red meat 1 time per week or more), they will proceed to the main study after reading and agreeing to the written consent form. Participants will then answer two questions about their belief in climate change. Participants will then view four messages in their ascribed conditions. After viewing all 4 messages, participants will answer a series of questions about the messages they viewed. Then, participants will answer a series of demographic questions. Participants will also answer questions about grocery shopping preferences.

Detailed description of the trial arms: This study is a three-armed between subjects' design. Participants will be randomized to view a set of four messages either about the environmental harms of meat production (intervention), the health harms of meat consumption (intervention), or about checking their credit score (control). The environmental and health harms messages were obtained from existing publicly available messages from the Meatless Monday campaign. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04562636
Study type Interventional
Source University of North Carolina, Chapel Hill
Contact
Status Completed
Phase N/A
Start date September 29, 2020
Completion date October 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2